Scinva Chemicals And Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
About Scinva Chemicals And Pharmaceuticals
Scinva Chemicals And Pharmaceuticals Private Limited (SCAPPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 June 2013 and has a history of 11 years and eight months. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Research & Development Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Narashima Murthy, Thimmaiah Kalpana, and Chetan Gangamahimanna serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24239KA2013PTC069657
-
Company No.
069657
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
12 Jun 2013
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
What products or services does Scinva Chemicals And Pharmaceuticals Private Limited offer?
Scinva Chemicals And Pharmaceuticals Private Limited offers a wide range of products and services, including Research and Development (R&D) Work, Product Development Research.
Who are the key members and board of directors at Scinva Chemicals And Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narashima Murthy
|
Director | 12-Jun-2013 | Current |
|
Thimmaiah Kalpana
|
Director | 25-Mar-2023 | Current |
|
Chetan Gangamahimanna
|
Director | 09-Jun-2023 | Current |
Financial Performance of Scinva Chemicals And Pharmaceuticals.
Scinva Chemicals And Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Scinva Chemicals And Pharmaceuticals?
In 2017, Scinva Chemicals And Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Scinva Chemicals And Pharmaceuticals?
Unlock and access historical data on people associated with Scinva Chemicals And Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Scinva Chemicals And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Scinva Chemicals And Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
